人细胞融合肝癌疫苗的制备及其融合细胞百分率的检测

• 作 者: 张从昕 季军捷 钱卫珠 范晓强 范瑞芳 卫立辛 吴孟超 郭亚军
• 机 构: 第二军医大学东方肝胆外科医院,第二军医大学东方肝胆外科医院,第二军医大学东方肝胆外科医院,第二军医大学东方肝胆外科医院,第二军医大学东方肝胆外科医院,第二军医大学东方肝胆外科医院,第二军医大学东方肝胆
• 出 处: 解放军医学杂志
• 发表日期: 2002年09期
• 关键词: 癌症疫苗 细胞融合 共刺激分子 融合率

手术取病人新鲜肝癌组织及部分脾脏 ,分离纯化、激活B细胞 ,应用PEG融合肝癌细胞与激活B细胞 ,经培养灭活制得肿瘤疫苗。同时测定了融合肝癌疫苗的融合率、冻存后复苏活细胞百分率。结果显示 ,3例融合细胞的融合率分别为 6 6 84 %、74 4 3%、76 5 5 % ,融合细胞经DMSO和甘油冻存后复苏活细胞百分率分别为 95 %、97%。研究表明 ,人细胞融合肝癌疫苗具有很高的融合率和冻存后复苏活细胞百分率 ,便于制备及储存 ,适合临床应用。

Surgical removal of fresh liver cancer tissue and part of the spleen, separation and purification, activation of B cells, the application of PEG fusion hepatoma cells and activated B cells, inactivated by culture obtained tumor vaccine. At the same time, the fusion rate of the fusion hepatocarcinoma vaccine was determined, and the percentage of viable cells recovered after cryopreservation. The results showed that the fusion rates of the three fused cells were 6 6 84%, 74 4 3% and 76 5 5%, respectively. The percentages of viable cells after resuscitation with DMSO and glycerol were 95% and 97%, respectively. Studies have shown that human cell fusion hepatocellular carcinoma vaccine has a high fusion rate and percentage of viable cells after cryopreservation, which is convenient for preparation and storage and is suitable for clinical application.